Shares of GDP Now Oversold

In trading on Thursday, shares of Goodrich Petroleum Corp. (GDP) entered into oversold territory, changing hands as low as $12.34 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In the case of Goodrich Petroleum Corp. , the RSI reading has hit 28.3 — by comparison, the universe of energy stocks covered by Energy Stock Channel currently has an average RSI of 56.7, the RSI of WTI Crude Oil is at 74.2, and the RSI of Henry Hub Natural Gas is presently 65.7.

START SLIDESHOW:
Click here to find out which 9 other oversold energy stocks you need to know about »

A bullish investor could look at GDP's 28.3 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.

Looking at a chart of one year performance (below), GDP's low point in its 52 week range is $11.16 per share, with $28.55 as the 52 week high point — that compares with a last trade of $12.52. Goodrich Petroleum Corp. shares are currently trading off about 17.5% on the day.

Goodrich Petroleum Corp.  1 Year Performance Chart

According to the ETF Finder at ETF Channel, GDP makes up 2.60% of the First Trust ISE-Revere Natural Gas Index Fund ETF ( FCG) which is trading lower by about 1.2% on the day Thursday.

More from Stocks

Dow Skids and Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Dow Skids and Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Spotify Announces Major Upgrade to Free Mobile App

Spotify Announces Major Upgrade to Free Mobile App

Looks like Coca-Cola's M&A Strategy Is Paying Off

Looks like Coca-Cola's M&A Strategy Is Paying Off

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug